PhD Position in Modular Phage-Based Nanocarriers for Radioligand Therapy at Belgian Nuclear Research Centre Belgian Nuclear Research Centre in Belgium

The Belgian Nuclear Research Centre (SCK CEN) is offering a full-time PhD position focused on the development of modular phage-based nanocarriers for advanced radioligand therapy. This research aims to revolutionize precision oncology by engineering bacteriophage-based vectors for targeted delivery of radiotherapeutic agents, addressing the challenges of specificity and off-target toxicity in cancer treatment. The project leverages the unique properties of bacteriophages, including biocompatibility and genetic modifiability, to create programmable carriers integrating tumor-targeting ligands, radiometal chelators, and bio-orthogonal functional groups.

Research activities will span molecular design, phage production, and preclinical validation in tumor models, utilizing modern genetic engineering, chemical bioconjugation, and radiochemistry techniques. The work is embedded in the RadioPharma Research expert group at SCK CEN, with mentorship from Van Houdt Rob and promotion by Abram Aertsen (KU Leuven). The research environment is at the forefront of nuclear and life sciences, providing opportunities for interdisciplinary collaboration and innovation in cancer therapy.

Eligibility requires a Master of Science or Master of Science in Engineering, with a background in bio-engineering, biology, or biochemistry. Candidates should demonstrate motivation for research in nanotechnology, radiotherapy, and biomedical innovation. The PhD studentship is expected to last four years, though specific funding details are not provided. The application deadline is March 31, 2026. Interested applicants should consult the SCK CEN PhD application guidelines and may contact the listed mentors for further information.

Key academic keywords include phage-based nanocarriers, radioligand therapy, nanotechnology, biomedical innovation, genetic engineering, chemical bioconjugation, and radiochemistry. The position is ideal for candidates seeking to contribute to life-saving nuclear therapies and advance cancer research in a dynamic, cutting-edge institutional setting.